^
Association details:
Biomarker:HOXD8 mutation
Cancer:Melanoma
Drug:Tafinlar (dabrafenib) (BRAF inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

Excerpt:
We performed whole exome sequencing on formalin-fixed, paraffin embedded (FFPE) tumors from 45 patients with BRAFV600 metastatic melanoma who received vemurafenib or dabrafenib monotherapy....Finally, a nonsense mutation in the HOXD8 gene was observed in a single resistant tumor from a patient with early resistance (Fig. 1B).
DOI:
10.1158/2159-8290.CD-13-0617